Spyre Therapeutics
SYRE
23 hedge funds and large institutions have $38.5M invested in Spyre Therapeutics in 2017 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 7 closing their positions.
58% more capital invested
Capital invested by funds: $24.4M → $38.5M (+$14.1M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 7
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
0.13% less ownership
Funds ownership: 1.67% → 1.54% (-0.13%)
12% less funds holding
Funds holding: 26 → 23 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$617K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$468K |
| 3 |
NI
Numeric Investors
Boston,
Massachusetts
|
+$223K |
| 4 |
Renaissance Technologies
New York
|
+$204K |
| 5 |
Bank of New York Mellon
New York
|
+$119K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VMI
VHCP Management II
New York
|
-$1.52M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$1.21M |
| 3 |
PA
Perceptive Advisors
New York
|
-$552K |
| 4 |
Norges Bank
Oslo,
Norway
|
-$275K |
| 5 |
SCM
Sio Capital Management
New York
|
-$105K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SIM
26
Spark Investment Management
New York
| – | -$52K | -480 | Closed |
|
27
Goldman Sachs
New York
| – | -$45K | -415 | Closed |
|
28
Acadian Asset Management
Boston,
Massachusetts
| – | -$2K | -19 | Closed |
|
|
TRCT
29
Tower Research Capital (TRC)
New York
| – | -$1K | -8 | Closed |
|
SYRE Hedge Fund Activity: Q1 2017 in Review
23 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Spyre Therapeutics (SYRE) for Q1 2017, worth a combined $38.5M — up 58% from $24.4M a quarter earlier.
Fund positioning in SYRE was balanced in Q1 2017: 7 funds opened new positions, 7 closed out, 5 added to existing stakes and 5 trimmed.
The largest buyer was OrbiMed, adding an estimated $617K. The largest seller was VHCP Management II, exiting entirely with an estimated $1.52M sold.
- 23 institutional investors held Spyre Therapeutics (SYRE) as of Q1 2017, down from 26 in Q4 2016.
- Funds reported $38.5M of Spyre Therapeutics stock for Q1 2017, up 58% quarter-over-quarter.
- 7 funds opened new Spyre Therapeutics positions in Q1 2017 and 7 closed out, a net change of 0 holders.
- The largest Spyre Therapeutics buyer in Q1 2017 was OrbiMed, an estimated $617K added.
- The largest Spyre Therapeutics seller in Q1 2017 was VHCP Management II, an estimated $1.52M sold.
Based on aggregated 13F filings for Q1 2017.